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ABSTRACT 
  
  
  
DEVELOPING A C.ELEGANS MODEL OF MARFAN SYNDROME  
By Pauline Effie Andreas Fotopoulos M.S.   
  
A thesis submitted in partial fulfillment of the requirements for the  
degree of  Master of Science in Biochemistry and Molecular Biology at Virginia Commonwealth 
University.  
  
Virginia Commonwealth University, 2014.  
 
Major Director: Young You, Department of Biochemistry and Molecular Biology   
   
Marfan Syndrome (MFS) is one of the most common monogenic diseases and affects 
approximately 1 in 5,000 individuals worldwide. The syndrome is characterized by elongated 
extremities, tall stature, slender frame, and cardiac, and vision abnormalities due to severe 
connective tissue defects. It is caused by mutations in the fbn1 gene, which encodes an 
extracellular matrix glycoprotein, and is required for proper cardiac and skeletal development 
and for sequestration of TGFβ (transforming growth factor beta) and BMP (bone morphogenetic 
protein) within the extracellular matrix (ECM).  
The primary objective of this study was to establish a C.elegans MFS model and use this 
model to determine which genes interact with a C.elegans fbn1 homolog, MUA-3 and ascertain 
the role of metabolic rate in the development of MFS pathology.  We isolated a temperature 
 
 
 xi 
sensitive mutant of mua-3, a fbn1 homolog. We found that at the fourth larval molt, when 
animals shed the exoskeleton and rebuild a new one, the mutants die due to extensive mechanical 
stress in connective tissue shown as fragmented internal structures. Using this mutant, an 
unbiased forward genetic screen to isolate the genetic interactors of the fibrillin gene homolog, 
was completed. A collagen gene, that has been implicated to genetically interact with a bone 
morphogenetic protein (BMP), was isolated. This suggests that mua-3(uy19) may interact with 
genes involved in TGFβ regulation during the L4 molt and that fibrillin-1, TGF-β, and 
metalloproteases may act in-concert to modulate TGFβ availability and connective tissue 
integrity in C. elegans. 
 In addition, we found that two independent mutations of mua-3 show temperature-sensitive 
phenotypes. Based on this result, we propose that increase of temperature aggravates the 
phenotype potentially due to increased metabolism. This hypothesis, if correct, will suggest a 
potential connection between metabolic rate and severity of MFS pathology.   
 
1 
 
1. Introduction 
1.1 Marfan Syndrome 
 Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder and among 
the most common monogenic diseases worldwide(Gao et al. 2010). The syndrome affects 
approximately 1 in 5000 individuals worldwide and occurs with high penetrance but notable 
inter- and intra-familial variation(Gao et al. 2010). Manifestations of the disease typically 
involve effects on the ocular, skeletal, and cardiovascular systems(Ramirez & Dietz 2007). 
Patients exhibit connective tissue and skeletal defects such as tall habitus, elongated extremities, 
joint hypermobility, scoliosis, striae, and chest wall deformities(Ramirez & Dietz 2007) (Figure 
1)(Joyce 2011). Cardiovascular manifestations range in severity from mitral valve prolapse, 
progressive aortic root enlargement, to acute aortic dissection(Ramirez & Dietz 2007).Ocular 
symptoms include myopia, retinal detachment, lens subluxation, and ectopia lentis 
(malpositioning of the lens with typical bilateral presentation) (Gao et al. 2010). MFS is caused 
by mutations in the fbn1gene(Ramirez & Dietz 2007). 
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Figure 1: Individual with MFS, shown here undergoing a clinical diagnostic test(Joyce 2011).    
  
 
 
 3 
 
(Joyce 2011) 
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1.2 Fibrillin-1  
 MFS results from mutations in the fbn1 gene which encodes an extracellular matrix 
(ECM) glycoprotein, fibrillin-1. Fibrillin-1 has a proline rich composition bias and is composed 
of 47 Epidermal Growth Factor (EGF)-like domains, 43 of which are able to bind to calcium 
(Figure 2)(Ramirez & Dietz 2007). These calcium binding EGF-like domains serve as the 
structural foundation for extracellular microfibrils in both elastic and non-elastic connective 
tissue throughout the organism(Zangwill et al. 2006). In addition, the protein contains nine 
transforming growth factor beta (TGF-β) binding domains (8scy/TB) which are highly 
homologous to latent TGFβ binding proteins(Gao et al. 2010). The N-terminus is considered a 
high affinity nonspecific binding site for all TGFβ family members(Sengle et al. 2008). Once 
secreted FBN-1 monomers aggregate and form beaded structures, which form macro-aggregates, 
microfibrils. Microfibrils may exist independently or become embedded in elastic fibers during 
embryogenesis (Figure 2) (Ramirez & Dietz 2007). Within these microfibrils, the functional role 
of FBN-1 is to sequester TGFβ and Bone Morphogenic Proteins (BMPs) in the ECM prior to 
activation. 
  
 
 
 5 
Figure 2: Organization and aggregation of fibrillin-1 proteins following secretion. A. 
Representative structure of fibrillin-1 including TGFβ binding domains and calcium binding 
Epidermal Growth Factor-like domains. B. Fibrillin-1 monomers develop into beaded structures 
that form macro-aggregates and constitute microfibrils which may exist independently or 
become incorporated into elastic fibers during embryogenesis. cbEGF-Calcium Binding 
Epidermal Growth Factor ; TB-Transforming Growth Factor β Binding Domain; Cys-cysteine .  
Image adapted from (Ramirez & Dietz 2007).  
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(Ramirez & Dietz 2007) 
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Over 1750 mutations in fbn1 are known to result in MFS and related disorders with over 
1000 mutations associated with MFS alone(Horiguchi et al. 2012; Gao et al. 2010). Frequently, 
these mutations result from premature termination codons or in-frame deletions(Gao et al. 2010). 
De novo mutations in FBN-1 account for 25% of MFS cases(Ramirez & Dietz 2007). FBN-1 is 
involved in cardiac development and skeletal development(Nistala et al. 2010). Skeletal 
development is affected by the modulation of osteoblast formation through TGFβ 
regulation(Nistala et al. 2010). FBN-1 is critical for modulating the TGFβ signal because it 
sequesters TGFβ and BMP (bone morphogenic protein) within the extracellular matrix (ECM) 
(Nistala et al. 2010) (Figure 3)(Handford 2012). 
  
 8 
Figure 3: Latent TGFβ complex shown bound to N-terminal region of fibrillin-1. TGFβ-
Transforming Growth Factor β; LTBP-Latent TGFβ Binding Protein. Image Adapted from 
(Handford 2012) 
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(Handford 2012) 
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1.3 TGF-β 
 TGF- β is involved in cell proliferation, differentiation, apoptosis, migration, immunity, 
angiogenesis, ECM production(Le Goff & Cormier-Daire 2012) and development (vascular, 
cardiac, lung, urogenital, craniofacial)(Massagué et al. 2000). An overview of TGFβ activation is 
given in Figure 4(Horiguchi et al. 2012). Synthesized as a preproprotein, monomers dimerize via 
a disulfide bond, resulting in a pro TGFβ homodimer(Horiguchi et al. 2012). A latency 
associated peptide (LAP) is non-covalently associated with TGF-β, forming the small latent 
complex (SLC)(Horiguchi et al. 2012). LAP imparts latency by preventing the growth factor 
domain from binding to its receptor or by inducing a conformational change of the growth factor 
domain that inhibits receptor binding(Sengle et al. 2008). The homodimer binds to a Latent 
TGFβ binding protein (LTBP) through a disulfide bond(Horiguchi et al. 2012). Furin convertase 
then cleaves the TGFβ prodimer to the mature TGF-β(Horiguchi et al. 2012). The large latent 
complex (LLC) forms when LAP, binds to the 8 cysteine motif TGFβ binding domain of LTBPs 
through a disulfide bond(Horiguchi et al. 2012). Latent TGFβ may either be secreted as SLC 
(LAP and TGF-β) or as LLC (SLC bound to LTBP) from the endoplasmic reticulum(Horiguchi 
et al. 2012; Le Goff & Cormier-Daire 2012). Soluble SLCs are unbound to LTBPs and not 
properly activated or targeted to the ECM, therefore the formation of the LLC is critical to TGFβ 
signaling(Horiguchi et al. 2012).  LTPBs will target the entire LLC complex to the ECM by 
binding to the N terminal region containing TGFβ binding sites on FBN-1, which may be 
embedded in elastic microfibrils(Horiguchi et al. 2012). Sequestration of the latent TGFβ 
complex prevents untimely TGFβ activation and excess signaling.  
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Figure 4: TGFβ processing within the endoplasmic reticulum, secretion, and subsequent 
sequestration within the ECM. 1) TGFβ monomers form homodimers. 2) TGFβ binds LAP and 
LTBP. 3) Furin convertase cleaves the proportion of TGFβ to form the mature TGF-β. 4) LLC, 
which includes TGF-β, LAP, and LTBP are secreted from the ER. 5) LTBP binds FBN-1 in 
microfibrils and is targeted to the ECM. Figure adapted from (Horiguchi et al. 2012).  
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(Horiguchi et al. 2012) 
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 TGFβ activation occurs following the release of the LLC from microfibrils and the ECM 
(Le Goff & Cormier-Daire 2012). TGFβ is released from the LLC through latent complex 
conformational modification or by LAP / LTBP degradation (Horiguchi et al. 2012). All 
activation mechanisms target LAP (Le Goff & Cormier-Daire 2012) although they may differ by 
cell type. Latent TGFβ can be activated by proteases, thrombospondin-1, reactive oxygen 
species, and integrins(Horiguchi et al. 2012). BMP-1, a metalloproteinase cleaves LTBP1 at two 
sites in the hinge region which releases SLC (Le Goff & Cormier-Daire 2012) and degrade LAP 
directly (Horiguchi et al. 2012), leading to TGFβ activation. Active TGFβ binds to its 
serine/threonine transmembrane receptors which in turn phosphorylate SMADs. SMADs return 
to the nucleus, accumulate, and regulate the transcription of genes(Ramirez & Dietz 2007). 
 
1.4 FBN-1 and TGFβ in Marfan pathology 
 Proteolytic cleavage can degrade the ECM, resulting in the release of LLC, and activation 
of latent TGFβ (Horiguchi et al. 2012). Within the ECM, one function of FBN-1 is to sequester 
TGFβ containing complexes to regulate TGFβ signaling. TGFβ complexes are released from 
FBN-1 when FBN-1 is proteolytically degraded or LTBP is cleaved. Normal individuals have 
sufficient FBN-1 rich microfibrils to sequester TGFβ prevent excess TGFβ activation. During 
proteolysis fibrillins become fragmented, and these fragments will interact with the N terminus 
of FBN-1. The FBN-1 fragment and microfibril interaction is followed by displacement of LTBP 
and subsequent release of LLC (Le Goff & Cormier-Daire 2012). Proteolysis of fibrillin rich 
microfibrils induces the expression of metalloproteinases and macrophage chemotaxis leading to 
aortic aneurysm progression(Guo et al. 2006; Booms et al. 2005). Structural defects in 
microfibrils, such as FBN-1 defects, result in a  failure to  sequester latent complexes, leading to 
 14 
excess TGFβ activation and a subsequent increase in TGFβ signaling mediated by SMADs(Le 
Goff & Cormier-Daire 2012; Ramirez & Dietz 2007; De Backer et al. 2009) (Figure 5. 2) 
(Ramirez & Dietz 2007) . One of the primary functions of  FBN-1 is to control TGFβ signal 
intensity (Ramirez & Dietz 2007). In patients with MFS, defects in FBN-1 lead to excess TGFB 
signaling, which results in the pleiotropic manifestations of disease (Figure 5)(Ramirez & Dietz 
2007).  
 Currently MFS is treated with β-adrenergic blockers to lower heart rate and slow aortic 
growth. However, this only ameliorates the deleterious symptoms of progressive aortic root 
enlargement and aortic dissection(Ramirez & Dietz 2007). To address this problem other 
medications have been developed, such as losartan.  Losartan is an angiotensin II 
receptor blocker(De Backer et al. 2009), which targets a cause of the disorder, by lowering TGFβ 
levels, reducing the expression of TGFβ activators and TGFβ receptors(Ramirez & Dietz 2007). 
Although it is clear that the relationship between FBN-1 and TGFβ contributes to the 
development of MFS, questions remain regarding the underlying mechanism. To further 
delineate how FBN-1 mutations modulate TGFβ signaling leading to the MFS phenotype, a 
model system can readily be genetically manipulated was necessary.  
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Figure 5: 1) Normal TGFβ sequestration and regulation by FBN-1. 2) Reduced microfibril 
formation due to FBN-1 mutations. Improper FBN-1 deposition allows the release of LLC and 
the subsequent activation of TGF-β. Once activated TGFβ binds to its serine/ threonine 
transmembrane receptor and mediates TGFβ induced transcriptional responses. TGFβ 
dysregulation and excess activation mediates the phenotypic outcomes associated with MFS 
pathology. Figure adapted from (Ramirez & Dietz 2007).  
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(Ramirez & Dietz 2007) 
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1.5 Developing a MFS Model in C.elegans  
C.elegans is a nematode that has long served as a model system for studying 
development, neurobiology, and behavioral biology(Riddle DL, Blumenthal T, Meyer BJ, et al. 
1997; Avery 2007). Most importantly, considerable conservation exists between this 
multicellular organism and humans, 35% of C.elegans genes have human homologs(Riddle DL, 
Blumenthal T, Meyer BJ, et al. 1997; Avery 2007). The complete cell lineage is well 
characterized and genes can be altered, removed, or added to the genome. Self-fertilization and 
cross-fertilization can also be manipulated(Riddle DL, Blumenthal T, Meyer BJ, et al. 1997; 
Avery 2007). The nematode has a short life cycle (Figure 6)(Altun, Z. F. and Hall 2005), small 
size, is transparent, easily cultivated in the laboratory, and generates 300-350 progeny(Riddle 
DL, Blumenthal T, Meyer BJ, et al. 1997; Avery 2007).  Forward and reverse genetic screens 
aim to determine the genetic basis of a phenotype and the phenotype which results from a 
specific sequence, respectively. These screens can be employed to determine potential genetic 
and protein interactions(Riddle DL, Blumenthal T, Meyer BJ, et al. 1997; Avery 
2007).Furthermore, we show that the molecular pathways and potential pathophysiology 
underlying MFS is conserved between mammals and worms.  
  
 18 
Figure6: C.elegans life cycle, including the duration of each life cycle stage at 25°C. Figure 
adapted from (Altun, Z. F. and Hall 2005).  
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  (Altun, Z. F. and Hall 2005) 
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1.6 Conserved Pathways and Homologs of MFS  
In C. elegans, fbn-1 and mua-3 are both homologs of human FBN-1 (Table 1)(Riddle DL, 
Blumenthal T, Meyer BJ, et al. 1997; Bercher 2001; Frand et al. 2005; Culetto & Sattelle 2000). 
MUA-3, encoded by the muscle attachment abnormal-3 (mua-3) gene, localizes to hypodermal 
cells in which body wall muscle adhesion occurs and sites of transhypodermal stress (Bercher 
2001). mua-3, is needed during postembryonic adhesion of the hypodermis to the cuticle(Bercher 
2001). A defect in mua-3 is characterized by progressive muscle detachment throughout larval 
development (Bercher 2001).  Fbn-1 is required for proper molting, specifically during the 
L3/L4 molt and L4/young adult molt(Frand et al. 2005). Complete knockout of mua-3 is lethal, 
while fbn-1 knockdown mutants exhibit molting defects, sterility, larval lethality, slow growth, 
and lay dead eggs(Riddle DL, Blumenthal T, Meyer BJ, et al. 1997; Bercher 2001; Frand et al. 
2005; Culetto & Sattelle 2000). This suggests that although both genes are homologous to fbn1 
in humans, these genes are not functionally redundant. Mutations in fbn-1 and mua-3 genes cause 
molting defects that can be attributed to defects in connective tissue(Bercher 2001). This 
demonstrates that C. elegans fibrillin genes have a conserved role in maintaining connective 
tissue integrity in both humans and C.elegans. The defects in molting that these C.elegans 
mutants show, suggest that the mechanical strain of molting (shedding and rebuilding the 
exoskeleton) could mimic MFS pathology.  
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Table 1: BLAST summary of human fbn1 homologs in C.elegans. The C.elegans, fbn-1 covers a 
greater sequence range of human fbn1, than mua-3. mua-3 exhibits a higher E-value and total 
score. Both fbn-1 and mua-3 are homologs fibrillin-1. (Altschul SF1, Gish W, Miller W, Myers 
EW 1990) 
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Table 1: Human FBN1 homologs in C. elegans  
Description Max 
Score 
Total 
Score 
Query 
cover 
E value Max 
identity 
C.elegans MUA-3 
isoform b 
181 1854 86% 5e-45 32% 
C.elegans MUA-3 
isoform a 
179 2421 86% 2e-44 45% 
C.elegans  FBN-1 
isoform h 
171 2375 91% 4e-42 45% 
(Altschul SF1, Gish W, Miller W, Myers EW 1990) 
 
 
 23 
Although a mua-3/fbn-1 and TGFβ relationship similar to their human counterparts has 
not been established, interestingly  in C. elegans, most genes that regulate body size are 
components of the TGFβ pathway(You et al. 2008; van der Linden et al. 2008), (Avery & You 
2012; Lee et al. 2012).  A homolog of human Bone Morphogenic Protein-1, a tolloid-like gene 
responsible for TGFβ activation, is dpy-31(Novelli et al. 2004). dpy-31 is essential to cuticle 
formation, embryonic/larval development at 25°C, and is expressed throughout the 
organism(Novelli et al. 2004). The effects of mutations in dpy-31 can be suppressed by gain of 
function mutations in dpy-17, a cuticle collagen required for posterior outgrowth(Riddle DL, 
Blumenthal T, Meyer BJ, et al. 1997; Buechner 2002; Brenner 1974; Novelli et al. 2004).  
1.7 Temperature Sensitivity    
Forward genetic screens can be used to isolate suppressors of temperature dependent 
phenotypes. Strains which exhibit temperature sensitivity include the muscle attachment 
abnormal-3 (mua-3) gene, a homolog to fbn1 in humans. mua-3 mutant alleles can exhibit 
connective tissue and molting defects similar to the MFS phenotype (Figure 7). A mua-3(uy19), 
131 amino acid in-frame deletion mutant and a mua-3 (rh195) single base pair substitution 
(missense) mutant were obtained. At the L4 molt, the stage prior to reproductive adulthood, mua-
3 (uy19) and an alternate allele, mua-3 (rh195) exhibit death and sterility phenotypes, 
respectively, at restrictive temperatures (Figure 7). However at permissive temperatures both 
mutant strains appear normal. The lethality and sterility phenotypes result from molting defects 
at the L4 stage. The molting defects may be attributed to a connective tissue defect. Worms 
exhibit internal organ misplacement, connective tissue detachment, or gonadal detachment. 
These symptoms mimic those observed in MFS. Clinical manifestations of MFS appear to be 
 24 
dependent on developmental stage, particularly in adolescence for humans, similar to the L4 
stage in worms which precedes reproductive adulthood.   
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Figure 7: A. Differential Interference Contrast (DIC) light microscopy image of mua-3(uy19) 
mutant at 20°C in the L4 stage. Connective tissue defect of mua-3 (uy19) mutant grown at a 
restrictive temperature. B. DIC image of mua-3(rh195) mutant at 25°C in L4 stage. Connective 
tissue defect of mua-3 (rh195) mutant grown at a restrictive temperature. Connective tissue 
defects of mua-3 mutant alleles including connective tissue detachment and internal organ 
misplacement are depicted. Images courtesy of Inwahn Lee.    
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Since considerable conservation in the gene and phenotype exists, we aimed to establish a 
C.elegans MFS model and determine how mua-3 contributes to the Marfanoid phenotype via its 
protein interaction network.  With the enriched resources, a C. elegans model for MFS can 
potentially be used to develop other effective drugs to treat MFS.  
1.8 Implications of Forward Genetic Screens   
Temperature variation experiments were used to characterize the phenotypes of the mua-
3 (uy19) and (rh195) mutant alleles. The temperature sensitive nature of the mua-3 (uy19) 
lethality phenotype permitted the use of an unbiased forward genetic mutant screen to isolate 
suppressors of mua-3(uy19) lethality. Several suppressors were isolated, the majority of which 
had smaller body size and slower growth rate. Therefore our results provide the first genetic 
evidence at the organismal level that the fibrillin-1 gene and the TGFβ pathway may interact.  
Upon complementation testing, we identified dpy-17 mutations as suppressors of the 
mua-3(uy19) phenotype from separate genetic screens. This validates our result that dpy-17 
suppresses the lethality phenotype of mua-3(uy19) and therefore suggests that DPY-17 and 
MUA-3 interact genetically during molting.  
 In this study, the primary aims were to establish a C.elegans MFS model and use this 
model to delineate the protein interaction network that contributes to the Marfanoid phenotype. 
Using C.elegans as a model for studying MFS, we characterized the temperature sensitive 
phenotype of mua-3(uy19) and used this characterization to identify genetic interactors of MUA-
3. One interactor, DPY-17, is known to genetically interact with DPY-31, a BMP-1 
homolog(Novelli et al. 2004). Together, our results suggest that fibrillin-1, TGF-β, and 
metalloproteases may act in-concert to modulate TGFβ availability and connective tissue 
integrity in C. elegans(Figure 8). These results also show the molecular conservation among 
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known genetic causes for Marfan or Marfan-related syndromes. Furthermore, this suggests that 
the molting process in C. elegans can be used to study Marfan pathology. 
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Figure 8: Potential interactions indirectly linking mua-3(uy19) to TGFβ pathway involvement.  
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2. RESULTS 
2.1 characterization of mua-3 (uy19) and mua-3 (rh195) mutants   
           To establish C. elegans as model for MFS it was necessary to thoroughly characterize the 
newly discovered mua-3 mutant alleles and phenotypes. Genome sequencing confirmed 
mutations in mua-3. One allele mua-3(uy19) contained a 131amino acid in-frame deletion and a 
separate allele mua-3 (rh195) possessed a single base pair substitution resulting in a missense 
mutation.   
2.2 mua-3(uy19) and mua-3(rh195) mutants appear larger than wild-type 
Up-regulation of genes and products within the TGFβ pathway typically confers a larger 
phenotype and is implicated in MFS pathology. To establish the mua-3 mutant as a model for 
MFS, we aimed to determine the characteristic lengths of TGFβ mutants and compare these 
measurements with length measurements of mua-3 mutants. Quantitative measurements of worm 
body length for mua-3(uy19) (YJ35), wild type (Bristol, N2), dbl-1 (ctIs40) (BW1940), lon-1 
(e185) (CB185), lon-2 (e678) (CB678), mua-3 (rh195)(OT136) were taken (Figure 9). Although 
mua-3(uy19) and mua-3(rh195) (data not shown) appear larger than wild type, results from 
experiments with separate procedures were inconsistent and inconclusive. Although, TGFβ 
mutant strains tended to larger than wild-type, there were no statistically significant differences 
among the strains. The inconsistency observed may be attributed in part to technical difficulties 
resulting from the nature of the connective tissue phenotype. The inherent weakness of the 
mutant strains’ connective tissue and the use of sodium azide to fix the worms onto agar slides, 
may have caused an exaggerated contraction, altering the length of the mutant. Demonstrating 
that mua-3mutants and mutants with TGFβ upregulation are larger in length would further 
characterize mua-3 mutants as Marfan-like and further establish the observed mua-3 phenotype 
as a model for MFS. 
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Figure 9: Averaged length of mua-3(uy19)(YJ35), wild type (N2), dbl-1 (ctIs40)(BW1940), lon-1 
(e185)(CB185), and lon-2 (e678)(CB678) strains at 72 hours post collection at L4 stage. An 
average of 5 worms/strain are represented in the graph (n=2). This data was generated with DIC 
microscopy. None of the length measurements are significantly different.   
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2.3 mua-3 mutants are molting defective and experience higher death rates via connective 
tissue defects during the L4 stage than wild type 
            Molting defects due to connective tissue detachment are pictured (Figures 7A and 7B). 
mua-3 (rh195) mutants exhibit gonadal detachment while mua-3 (uy19) mutants exhibit internal 
organ misplacement and connective tissue detachment. Temperature variation and time course 
experiments were performed with mua-3(uy19) and wild type strains to identify the stage at 
which mua-3(uy19) deaths occur and determine whether an increase in temperature increases 
mua-3(uy19) lethality via connective tissue defect (Figure 7A). These results provide evidence 
that lethality occurs during the L4 stage, the stage prior to reproductively active adulthood, at 
restrictive temperatures (Figure 10 A and B). At the L1, L2, and L3 stages there were no deaths 
observed and only a few deaths were observed at stages past L4. The time required for worms to 
mature from L1 to L4 at 25°C is approximately 30 hours. The L4 stage will last for at least 6 
hours. At 20°C, maturation from L1 to L4 requires about 38 hours, while at 15°C maturation 
requires 63 hours. The L4 stage at 20°C and 25°C will last for approximately 9 hours. The 
majority of death occurred within the L4 stage timeframe designated above, for 15°C, 20°C, and 
25°C respectively. 
At the permissive temperature, 15°C, mua-3 and wild type worms at the L4 stage had a 
death rate of, nearly zero and exhibited no molting defects (Figure 10 C). However, at restrictive 
temperatures, 20°C and 25°C, there was a statistically significant difference between deaths 
observed in wild type and mua-3 strains. This provides evidence that lethality occurs only at 
restrictive temperatures (20°C and 25°C). Furthermore, lethality was enhanced at 25°C in 
comparison to 20°C.  
 
 
 35 
The difference in survival of mua-3 mutants between permissive and restrictive 
temperatures indicates that connective tissue defects and lethality increase with increasing 
temperatures. The results of the temperature variation and time course experiments support the 
assertion that it is specifically at the L4 stage that mua-3 deaths occur. At higher temperatures, 
25°C, the mechanical strain of molting increases, metabolic rate accelerates, and protein folding 
may be affected.  Higher temperatures correspond to increased lethality and therefore may be 
attributable to an increase in metabolic rate or improper folding of the protein. Characterization 
of the mua-3 mutant phenotype allowed us to perform an unbiased forward genetic screen in 
which we could isolate suppressors of the connective tissue defect, lethality phenotype.    
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Figure 10: A. Time course of percent survival observed for mua-3 and wild type strains at 20°C. 
n=6 worms/treatment; average of data at each time point is shown. The difference is statistically 
significant at P < 0.01.  B. Time course of percent survival observed for mua-3 and wild type 
strains at 25°C. n=8 worms/treatment; average of data at each time point is shown. The 
difference is statistically significant at P < 0.01. C. Time course of percent survival observed for 
mua-3 and wild type strains at 15°C. n=6 worms/treatment; average of data at each time point is 
shown. The difference is not statistically significant.  
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Table 2: 841 fold decrease in progeny from wild type to mua-3(rh195)(OT136) at the 25°C, 
restrictive temperature. The graph represents an average of the total number of progeny produced 
by worms at 25°C (n=10). The difference is statistically significant at P < 0.001.    
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Strain Number of 
Progeny 
+ 1682 
mua-3 2 
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2.4 mua-3(rh195) mutants experienced significantly higher sterility rates at the restrictive 
temperature than wild type  
To establish C. elegans as model for MFS, it was necessary to characterize the phenotype 
associated with mutations in mua-3(rh195). At the permissive temperature, 20°C, there is no 
noticeable difference in the number of progeny produced by the mua-3 (rh195) mutant and wild-
type worms. However, mua-3(rh195) experienced much higher connective tissue defect and 
sterility rates than wild type when grown at the restrictive temperature, 25°C. Specifically, 
gonadal detachment occurs in mua-3(rh195) mutants at 25°C. When grown at the restrictive 
temperature the rate of sterility for mua-3 mutants nears 100% (Table 2). Evidence of the rate of 
sterility for this mutant allele is provided by data in which total offspring of individual worms 
was counted. We have shown that the difference in the number of progeny produced by wild 
type and mua-3 (rh195) worms at the restrictive temperature, 25 °C, is statistically significant. 
The 841 fold decrease in progeny from wild type to mua-3(rh195) at restrictive temperatures 
(Table 2) indicates that mua-3(rh195) mutants are sterile at restrictive temperatures. 
2.5 Suppressors of the MFS phenotype of mua-3(uy19) have been discovered 
To identify suppressors of the mua-3(uy19) MFS phenotype, an unbiased forward genetic 
F2 screen was performed using Ethyl Methyl Sulfonate (EMS) mutagenesis. It was determined 
that the lethality observed  at the 25°C, restrictive temperature, was far more severe than 20°C 
and would serve as a better treatment for screening the temperature sensitive mutants. A 
secondary temperature screen at 25°C was performed to identify and remove sterile (worms that 
produced no progeny) and escaper worms (worms that produced non-viable progeny). 
Approximately 20, F2 potential suppressors were isolated (Table 3). The trend among 
 
 
 41 
suppressors of mua-3(uy19) lethality phenotype is that of shortened body length, slower growth, 
and slower egg laying (Table 3). These experiments allowed us to determine potential mua-
3(uy19) interactors and begin to form a picture of how mua-3(uy19) may be involved in TGFβ 
regulation and therefore MFS pathology. It provides the foundation upon which we may search 
for and establish a mechanism by which MFS progresses.   
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Table 3: Characterization of isolated suppressors of the mua-3(uy19) lethality, MFS-like, 
phenotype (Suppressor Of Drop Dead, SODD). SODD 1-SODD 15 includes suppressors isolated 
from the first screen. SODDD 16-SODD 27 includes suppressors isolated from the second 
screen.     
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SODD Extreme  
Short 
Length 
Short 
Length 
Wild-
type 
length  
Long 
Length 
Extreme 
Long 
Length  
Disproportioned Thin Fat  Hooked 
 
1  x     x  x 
3   x       
4       x   
5   x      x 
6  x     x   
7  x     x   
8  x     x   
9  x     x   
10  x     x  x 
11 x     x    
12 x     x    
14 x     x    
15  x     x   
16  x     x   
17  x     x  x 
18 x     x    
19 x     x    
20   x    x   
21     x  x   
22  x     x   
23 x     x    
24   x x    x  
25   x       
26   x x      
27   x x      
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SODD Pale Dark Slow 
Growth  
Slow -
abnormal 
Motility 
Bands Crumpled- 
Misplaced 
structures 
Agitated 
Behavior 
Blister Round 
1 x         
3     x x    
4          
5       x   
6 x         
7 x   x      
8 x        x 
9  x        
10         x 
11  x x x     x 
12  x x x      
14  x x x      
15    x      
16   x x      
17 x  x x    x  
18          
19  x        
20     x     
21     x     
22 x  x x x     
23  x        
24          
25          
26  x        
27  x        
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Figure 11: SODDs rescue mua-3(uy19) lethality at the restrictive temperature, 25°C. Percentage 
of deaths associated with SODD, mua-3, and wild type strains grown at 25°C for 48 hours. 
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2.6 Isolated suppressors rescue mua-3 (uy19) lethality phenotype at restrictive 
temperatures 
            To confirm the rescue of mua-3(uy19) mutated worms by the isolated mua-3(uy19) 
lethality phenotype suppressors, SODDs, mua-3 mutants and wild type strains were treated at 
25°C for 48 hours. The percentage of death for several strains was determined (Figure 11). mua-
3 mutants showed 87% death at 25°C, while wild type and SODD 9 showed 0% death.  SODD 
19 demonstrated a 2% death, SODD 16 exhibited 32% death, and SODD 3 exhibited 7% death. 
This confirms that the isolated suppressors of the mua-3(uy19) lethality phenotype are capable of 
inhibiting lethality at restrictive temperatures. The experiment allowed us to move forward in 
identifying and characterizing the SODDs.  
2.7 dpy-17 mua-3(uy19) mutants were isolated from separate genetic screens   
A series of complementation tests among the isolated suppressors of the mua-3(uy19) 
lethality phenotype, were employed to identify and locate suppressors. Complementation tests 
among unidentified Dpy suppressor and Sma suppressor phenotypes were performed (Table 4). 
Unidentified suppressor hermaphrodites were crossed with wild-type males. The F1 progeny 
males were crossed with an alternate unidentified suppressor. The F1 progeny of this cross were 
counted and phenotyped as Dpy: wild-type and hermaphrodite: male. If the phenotypic ratio was 
1:1, suppressors failed to compliment. Following this, further complementation testing between 
unknown Dpy suppressors and known dpy mutants were performed using the procedure and 
criteria described above. We determined that 5 suppressors, S9, S19, S11, S18, S23, failed to 
complement dpy-17 (e164)(CB164) (Table 4). The dpy-17 suppressors of lethality are severely 
disproportioned and small in size.  Suppressors containing a mutated dpy-17 gene were isolated 
from two separate forward genetic screens performed on different days. This indicates that not 
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all isolated suppressors with the mutated dpy-17 gene were derived from one mother.  Through 
complementation testing we have identified dpy-17 as a mua-3 interactor. Further 
complementation testing may reveal other mua-3 interactors and enable us to elucidate the 
mechanisms by which mua-3 may be involved in TGFβ regulation and MFS disease progression.  
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Table 4: Summary of Complementation Tests among SODDs (Isolated Suppressors of mua-3 
Lethality) 
 
  
 50 
   
Strain Fails To Complement  Complements 
dpy-17 
(CB164) 
S11, S18, S19, S23 
 
S9 
 
S7, S22 
S6 
 
S10 
S22 S16 
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Figure 12: Percentage of deaths observed for mua-3(uy19)(YJ35) worms treated with and without 
5ng/ml aztreonum at 25°C (average of 4 worms/treatment). There was no statically significant 
difference between the aztreonum treated and non-treated conditions. Aztreonum did not 
sufficiently rescue mua-3 (uy19) lethality via connective tissue defect.   
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2.8 Alterations in nutritional input which decrease metabolism are not sufficient to rescue 
mua-3(uy19) lethality  
To determine if mua-3 mutants are sensitive to fluctuations in metabolic rate mediated by 
nutritional input, phenotype was assessed at various food quality levels and temperatures (Figure 
12). Aztreonum, an inhibitor of bacterial cell wall division, will increase the size of bacteria and 
thereby decrease food quality. This should reduce metabolic rate and alleviate connective tissue 
defects leading to lethality. The percentage of death was recorded for both the aztreonum treated 
and untreated mua-3(uy19) mutants at 20°C and 25°C. There was no statistically significant 
difference in the percentage of death observed at either temperature or aztreonum concentration. 
This result indicates that 5ng/ml aztreonum is insufficient to rescue mua-3 (uy19) lethality and 
alleviate connective tissue defect. However, this does not exclude the possibility that more 
severe alterations in nutritional input may alleviate mua-(uy19) connective tissue defects and 
lethality.    
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3. DISCUSSION 
 
3.1  mua-3 connective tissue defects mimic MFS Pathology  
The primary aims of this study were to establish a C.elegans MFS model by determining 
how mua-3, a fibrillin homolog contributes to the Marfanoid phenotype. Sequence homology and 
similar phenotypic consequences of mutated genes we and others found indicate the role of 
fibrillin genes in C.elegans and humans is conserved. We have demonstrated that mua-3 mutant 
alleles exhibit connective tissue and molting defects, mimicking the MFS phenotype. The 
lethality mua-3 occurs during molting and can be attributed to connective tissue defects that lead 
to internal organ misplacement, connective tissue detachment, or gonadal detachment. These 
connective tissue defects mimic the symptoms observed in MFS patients.  
 
3.2 The TGFβ pathway regulates body size in C.elegans and may interact with mua-3  
The temperature sensitive nature of the mua-3 (uy19) lethality phenotype permitted the 
use of an unbiased forward genetic screen to isolate suppressors of mua-3(uy19) lethality. 
Several suppressors were isolated, the majority of which had smaller body size and slower 
growth rate. In C. elegans, most genes that regulate body size are components of the TGFβ 
pathway and all TGFβ mutants exhibit size defects (Fujiwara et al. 2002; Fernando et al. 2011) 
Therefore our results provide the first genetic evidence at the organismal level that the 
fibrillin-1 gene and the TGFβ pathway may interact.  
3.3 Latent TGFβ is sequestered by fibrillin-1 and activated by BMP-1, which may have a 
role in mediating MFS pathology   
 Upon complementation testing, we identified dpy-17 mutations as suppressors of the 
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mua-3(uy19) lethality phenotype from two independent genetic screens. dpy-17 encodes a cuticle 
collagen required for posterior outgrowth of C. elegans. That we isolated dpy-17 mutants as a 
suppressor of mua-3 twice from two independent screens strongly suggests that DPY-17 and 
MUA-3 interact genetically during L4 molting. Interestingly, gain of function mutations in dpy-
17, can suppress the  dpy-31phenotype (Novelli et al. 2004). DPY-31is essential to cuticle 
formation, embryonic/larval development, is expressed throughout the organism, and is a 
homolog of Bone Morphogenic Protein-1, a tolloid-like gene responsible for TGFβ  activation 
(Novelli et al. 2004). Therefore, in worms DPY-31 and in humans the BMP-1 metalloprotease 
may be involved in TGFβ dysregulation, a process that has been previously implicated in MFS 
disease progression(Ramirez & Dietz 2007).       
 A disruption in fbn1 microfibrils can release latent TGFβ(Ramirez & Dietz 2007). 
Subsequent TGFβ activation results in the production of metalloproteases, and may include 
BMP-1. BMP-1 may further increase TGFβ activation, by freeing latent complexes from LTBP 1 
or degrading LAP(Le Goff & Cormier-Daire 2012). Additionally fibrillin-1 sequesters TGFβ 
family members including BMPs (Nistala et al. 2010)and it may be that both BMP-1 and latent 
TGFβ are sequestered by fibrillin-1 rich microfibrils. A disruption in fbn1 may free latent TGFβ 
and activators like BMP-1. This may contribute to TGFβ dysregulation and MFS pathology. 
3.4  mua-3 (uy19) lethality is observed during the L4 stage and may result from mechanical 
strain, insufficient stage specific cuticle collagen interactions, or insufficient levels of MUA-
3, required for molting 
 Clinical manifestations of MFS appear to be dependent on developmental stage, 
particularly in adolescence for humans, similar to the L4 stage in worms which precedes 
reproductive adulthood. There are several plausible reasons for why mua-3(uy19) mutants died at 
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the L4 stage although none have been confirmed experimentally. The MUA-3 protein with 131 
amino acid deletion might be able to function until L4 molting but might not be sufficient for L4 
molting.  The mechanical strain during L4 molt could be more stressful than other molts and 
result in the lethality phenotype in this particular mutant. An alternative to this hypothesis is that 
the deleted region of MUA-3 in this mutation contains a domain required for an interaction with 
an L4 stage specific collagen. This scenario suggests that L4 lethality may be attributed to the 
specific 131 amino acid in frame deletion mutation of mua-3 (uy19). If mua-3 interacts with 
multiple cuticle collagens, another deletion may result in lethality at a different stage.    
3.5 Restrictive Temperatures may disrupt protein folding and increase metabolic rate, 
potentially exacerbating MFS phenotype 
Currently MFS is treated with β-adrenergic blockers to lower heart rate, slow aortic 
growth, and metabolic rate. However, this only ameliorates the deleterious symptoms of 
progressive aortic root enlargement and aortic dissection(Ramirez & Dietz 2007). As 
temperature increases, metabolic rate and other processes accelerate. If metabolic rate has any 
role in regulating disease progression we would expect that an increase in temperature and 
metabolic rate would exacerbate the MFS-like phenotype whereas a decrease in metabolic rate 
should alleviate the phenotype. Temperature variation experiments are consistent with the 
possibility that lethality and sterility phenotypes are exacerbated by higher metabolic rate and 
alleviated by lower metabolic rate. 
 
Additionally higher temperatures may disrupt proper protein folding. At lower 
temperatures the protein produced by mua-3 may be more stable or capable of folding properly. 
Alternatively the worms may have a protein which is 50% functional at both high and low 
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temperatures. At low temperatures 50% functionality may be sufficient for survival while at high 
temperatures 50% functionality of the protein is insufficient. Insufficient levels of functional 
protein may result in the loss of connective tissue integrity in a temperature dependent manner.  
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4. Conclusions 
Using C.elegans as a model for studying MFS, we characterized the temperature sensitive 
phenotype of mua-3 and used this characterization to identify genetic interactors of MUA-3. One 
interactor, DPY-17, is known to genetically interact with DPY-31, a BMP-1 homolog(Novelli et 
al. 2004). Together, our results suggest that fibrillin-1, TGF-β, and metalloproteases may act in-
concert to modulate TGFβ availability and connective tissue integrity in C. elegans. These 
results also show the molecular conservation among known genetic causes for Marfan or 
Marfan-related syndromes. Furthermore, this suggests that the molting process in C. elegans can 
be used to study Marfan pathology.  
 
4.1 Future Directions  
In the future whole genome sequencing can be used to confirm suppressor mutations and 
further characterize mutations in all isolated suppressors. An eat-2 loss of function mutation may 
be introduced into mua-3 mutants to test whether lowering metabolic rate by reducing food 
intake alleviates the MFS phenotype and decreases the severity of the connective tissue defect. 
Additionally, RNAi can be used to inhibit the expression of molecules involved in the TGFβ 
pathway within mua-3(uy19) mutated worms. This technique can be employed to determine the 
molecular mechanisms by which the severity of connective tissue defect and MFS pathology is 
enhanced.  
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5. METHODS 
5.1 C. elegans strains and culture conditions 
Worms were routinely grown on NGMSR plates(Avery 1993). All worms were 
maintained at 20°C on E. coli HB101(Sulston JE 1988) except for mua-3(uy19) (YJ35) mutant 
worms which were maintained at 15°C. The wild-type strain was C. elegans variant Bristol, 
strain N2. Mutant strains used include mua-3(rh195) (OT136), mua-3(uy19)(YJ35), dbl-1 
(ctIs40)(BW1940), lon-1 (e185)(CB185), dpy-17 (e164) (CB164) and lon-2 (e678) (CB678).  
Eggs were isolated via hypochlorite treatment(Sulston JE 1988) then harvested in M9 buffer to 
obtain a synchronous population.  
5.2 Time course Experiments 
Synchronized populations of mua-3 alleles and wild type strains were transferred to 
E.coli HB101 seeded NGM plates at the L1 stage and cultivated at either 20°C or 25°C in 
triplicate. Synchronized populations of approximately 100 mua-3 and wild-type L1s were plated 
onto each plate. At the L4 stage (after 38 hours at 20’C and 30 hours at 25’C), the number of 
dead worms and total number of worms were counted to determine percent survival of mua-3 
and wild-type strains at each hour from 38, 30 hours.  
5.3 Sterility Phenotype Characterization 
To determine the number of offspring produced by individual worms of the mua-
3(rh195) (OT136) mutants and wild type, approximately10 L4s of each strain were transferred 
singly to E. coli-seeded NGM plates and their progeny counted. Each worm was transferred to a 
new plate every day to avoid being crowded and to visualize all the progeny easily. Progeny 
were counted three days later. 
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5.4 Body Length Measurements 
Body lengths of the wild type (N2), mua-3(rh195) (OT136), mua-3(uy19)(YJ35), dbl-1 
(ctIs40)(BW1940), lon-1 (e185)(CB185), and lon-2 (e678) (CB678) were measured.. Worms of 
each strain were picked at the L4 stage and measured their body lengths at 24, 48, and 72 hours 
using Differential Interference Contrast (DIC) light microscopy at the settings of 10X objective, 
III condenser, 0.3 aperture, 100ms exposure and a scale bar of 100 micrometers was used in 
making the measurement calculations.  
Additionally, in order to allow worms to successfully pass the L4 stage, measurements 
were taken after incubating L4s of wild-type (N2), mua-3(rh195) (OT136), mua-3(uy19)(YJ35), 
dbl-1 (ctIs40)(BW1940), lon-1 (e185)(CB185), and lon-2 (e678) (CB678) at 15°C for 24 hours 
then transferring the strains to 20°C. Worms were imaged using DIC microscopy as described 
above. 
To determine the size and potentially enhance the long length phenotype, synchronized 
populations of mua-3(rh195)(OT136) mutant and wild type were transferred to 25°C . Worms 
were imaged at approximately 24 and 48 hours after L4 stage using DIC microscopy as 
described above.  
  
5.5 Nutritional Variation 
LB agar was prepared with and without 5 ng/ml concentration of aztreonam, which 
decreases food quality by inhibiting bacterial cell wall division (ref). Following agar preparation, 
plates were seeded with E. coli HB101 (incubated at 37°C for 12 hours and cooled for 24 hours 
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prior to use). mua-3 mothers (n=4) were then moved to aztreonam-treated and untreated plates 
(in duplicate). Aztreonam-treated and untreated plates were then placed either at 20°C or 25°C. 
Mothers were aspirated after 5 hours, in order to synchronize the population. Forty-eight hours 
later, the number of dead worms and total number of worms were counted to determine percent 
death.  
5.6 Determination of Temperature for Suppressor Screen 
Using age matched plates, wild type and mua-3 mutant strains at the L1 stage were 
transferred to 20°C or 25°C (duplicate). At the L4 stage, the number of dead worms and total 
number of worms were counted to determine percent survival. This was done to establish an 
appropriate temperature treatment for use in an F2 suppressor screen of mutagenized mua-3 
worms.   
5.7 Suppressor Screen  
mua-3(uy19) (YJ35) worms were collected at L4 stage and randomly mutagenized with 
ethyl methane sulphate (EMS) (Riddle DL, Blumenthal T, Meyer BJ, et al. 1997; Brenner 1974). 
Po worms were plated onto E.coli HB101 seeded plates and moved to 15°C. F1 progeny were 
synchronized and remained at 15°C. The homozygous, F2 generation was synchronized and 
moved to 25°C.  Survived worms (suppressors of mua-3 mutant phenotype, SODD) were 
isolated.  
5.8 Secondary screen 
Individual suppressors of the mua-3 mutant phenotype were isolated and moved to 
individual plates at the restrictive temperature, 25°C. Sterile (worms that produced no progeny) 
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and escaper worms (worms that produced over 90% of non-viable progeny) were removed. F2s, 
approximately 20 were isolated and maintained at 25°C.    
5.9 Complementation Test 
Complementation tests among unidentified Dpy phenotypes and Sma phenotypes were 
performed. Unidentified suppressor hermaphrodites were crossed with wild-type males. The F1 
progeny males were crossed with an alternate unidentified suppressor. The F1 progeny of this 
cross were counted to calculate the percentage of Dpy. The percentage of males in the population 
was also counted to determine whether Dpy progeny is from cross or self-fertilization. If 50% of 
the progeny is Dpy, suppressors failed to complement each other.  
5.10 Confirmation of Suppressors  
To determine if the suppressors of mua-3 lethality (Suppressor Of Drop Dead, SODD) 
isolated from the screen are capable of rescuing the mua-3 (uy19) mutant at 25°C, mua-3, wild 
type, and SODD strains were synchronized, individually plated, and moved to 25°C. The number 
of dead worms and total number of worms were counted to determine percent survival of each 
strain. 
5.11 Analysis 
Student t-tests were performed to determine statistical significance.   
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Appendix A 
Quiescence is marked by inactivity, reflecting the nutritional state of full feeding. The 
behavior is mediated by TGFβ, insulin, and cGMP (cyclic guanosine monophosphate) pathways 
(You et al. 2008). In this study, we aimed to determine whether increasing cGMP levels through 
administration of sildenafil citrate increases satiety quiescence. Sildenafil citrate, a 
phosphodiesterase inhibitor, prevents the breakdown of cGMP and therefore increases cGMP 
signals. Sildenafil citrate has been shown to provide protective effects against weight gain on 
high fat diets both in humans and mice. We found that quiescence following sildenafil citrate 
treatment at certain concentrations was enhanced. Statistical significance was observed in only 
one set of data and not reproduced in subsequent experiments. However inconclusive our results 
are, we could observe the trend that sildenafil citrate could potentially alter satiety quiescence, 
therefore could be further used as a pharmacological tool to study how enhanced cGMP 
signaling can affect satiety quiescence in C. elegans. Addressing this will help to study whether a 
commercially available drug such as sildenafil citrate can be used to treat obesity to suppress 
appetite control.     
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A. Introduction 
A.1 Obesity 
Obesity is the leading cause of the two deadliest diseases in the US, cardiovascular disease and 
type 2 diabetes. Yet, the underlying molecular mechanisms that contribute to obesity are poorly 
understood.  Nonetheless, Valentino et.al.(Valentino MA, Lin JE, Snook AE, Li P, Kim GW, 
Marszalowicz G, Magee MS, Hyslop T, Schulz S 2011) recently uncovered that a cGMP 
pathway is stimulated upon feeding to suppress appetite. Similarly, recent reports demonstrate 
that sildenafil citrate, a medicine that inhibits degradation of cGMP to treat erectile dysfunction, 
has protective effects against weight gain on a high-fat diet both in humans and mice. Together, 
these findings highlight an essential role for cGMP signaling (Valentino MA, Lin JE, Snook AE, 
Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S 2011)in appetite and 
metabolism and further suggest that well-established pharmacological inhibitors may be effective 
treatments for obesity. 
A.2 Satiety Quiescence  
Quiescence results from satiety and is indicated by the behavioral sequence of satiety, in which 
animals stop feeding and moving and rest(Sengenès et al. 2000).  The main regulators of 
quiescence are TGFβ, insulin, and cGMP. The cGMP pathway is particularly important because 
a mutation in cGMP-dependent kinase (PKG) completely abolishes satiety quiescence(You et al. 
2008). However, in C.elegans, the cellular and molecular mechanisms by which cGMP regulates 
satiety quiescence is unclear(You et al. 2008).  
cGMP signaling pathways regulate phototransduction, vasodilation, glucagon secretion, 
mitochondrial biogenesis, brown adipocyte tissue formation, and cellular metabolism(Mitschke 
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et al. 2013).  cGMP signals also participate in sleep and feeding in invertebrates(Fujiwara et al. 
2002; You et al. 2008).  Additionally cGMP contributes to adipocytokine secretion, adipocyte 
size, and maintenance of healthy white adipose tissue (WAT)(Mitschke et al. 2013).  
A.3 cGMP 
cGMP mediates effects through cyclic nucleotide gated ion channels, cGMP regulated 
phosphodiesterases, and cGMP-dependent protein kinase G (PKG)(Francis et al. 2010). In the 
C.elegans daf-11mutant, the loss of function of a membrane bound guanylyl cyclase, a producer 
of cGMP(Jennissen et al. 2012), will result in shorter quiescence than wild type(Mitschke et al. 
2013; Birnby et al. 2000). PKG is activated by cGMP (Jennissen et al. 2012) and responsible for 
olfactory adaptation, locomotion behavior, regulating body size(Fujiwara et al. 2002; Hirose 
2003; L’Etoile et al. 2002), lipolysis (via hormone sensitive lipase)(Sengenès et al. 2000), and 
has a role in food seeking behavior(Ben-Shahar et al. 2002) (Figure 13)(You et al. 2008). The 
gain of function mutation of PKG (EGL-4) is smaller than wild type and exhibits 
quiescence(Raizen et al. 1995) while the loss of function is larger than wild type and roams more 
often (Raizen et al. 1995). Data from these experiments show decreases in cGMP levels or 
cGMP signaling results in less quiescence and that cGMP is crucial to normal satiety quiescence.  
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Figure 13: Pathway for induction of satiety quiescence mediated by cGMP, TGFβ, and insulin. 
(You et al. 2008) 
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(You et al. 2008) 
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A.4 cGMP Involvement in Obesity Prevention and Insulin Sensitization   
White adipocytes contain the largest energy reserves and possess endocrine 
functions(Mitschke et al. 2013). cGMP induces browning of WAT through the cGMP/PKG1 
pathway(Mitschke et al. 2013). PKG-1 regulates cell size, adipokine secretion, and is required 
for the differentiation of white adipocytes into brown adipocytes(Haas et al. 2009). Brown 
adipocytes metabolize fatty acids (Antin et al. 1975); this process depends on the number of 
mitochondria and amount of uncoupling protein-1 expressed(Cannon & Nedergaard 2004). By 
uncoupling mitochondorial oxidative phosphorylation, UCP-1 dissipates the energy from fatty 
acids as heat (Okamatsu-Ogura et al. 2013) (Cannon & Nedergaard 2004) and is only seen in 
brown adipose tissue (BAT)(Antin et al. 1975). Following treatment with cGMP, white 
adipocytes undergo phenotypic trans-differentiation to become beige adipocytes (Mitschke et al. 
2013). Beige adipocytes express PGC-1 alpha, express high levels of mitochondria and UPC-1 
(due to cGMP/PKG1 signaling)(Nedergaard & Cannon 2010; Lowell & Spiegelman 2000) and 
mediate norepinephrine thermogenesis. Although developmentally distinct, brown and beige 
adipocytes function physiologically to generate heat via UCP-1, thus protect against hypothermia 
and obesity(Wu et al. 2012; Okamatsu-Ogura et al. 2013; Mitschke et al. 2013) .  cGMP’s role in 
brown adipocyte differentiation in white adipose tissue implies that cGMP may be involved in 
obesity prevention (Mitschke et al. 2013).  
Adipokines are involved in glucose metabolism and in, inflammation, and contribute to a 
higher risk of diseases associated with obesity (Mitschke et al. 2013). Following cGMP 
treatment (PKG1 activation), adiponectin levels increased whereas proinflammatory cytokine 
levels were decreased(Mitschke et al. 2013). Proinflammatory cytokines are typically 
upregulated in obese individuals and add to macrophage infiltration into adipose tissue(Mitschke 
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et al. 2013) whereas low levels of adiponectin are associated with insulin resistance and 
obesity(Arita et al. 2012). cGMP’s role in proinflammatory adipokine reduction and adiponectin 
enhancement suggests cGMP may be decrease insulin resistance (Mitschke et al. 2013).  
  
A.5 Sildenafil Citrate  
Sildenafil citrate has been shown to endow protective effects in weight gain from high fat 
diets.  This PDE inhibitor is selective for PDE 5 and will increase cGMP levels by preventing 
hydrolysis of cGMP(Valtcheva et al. 2009; Burkhardt et al. 2000). Chronic cGMP hydrolysis 
inhibition increases insulin action while short term cGMP hydrolysis inhibition increases 
browning of white adipocyte tissue. Short term sildenafil citrate treatment will increase UPC-1 
expression and PGC-1 alpha expression in WAT (Mitschke et al. 2013). This is indicative of 
transdifferentiation into brown adipocytes. Increased browning of WAT, referred to as beige 
adipose tissue, and increased brown adipocyte levels lead to greater energy expenditure and 
weight loss(Mitschke et al. 2013; Ayala et al. 2007).  
 
Using the phosphodiesterase inhibitor, sildenafil citrate, we aimed to test whether 
increased cGMP levels would enhance quiescence.  We treated worms with various 
concentrations of sildenafil citrate, monitored locomotion using the YouWorm Tracking system, 
a custom written program in Matlab and analyzed the locomotion data with a custom written 
program in Mathematica.  Quiescence was indicated by a lower average speed and higher time at 
low speed for worm locomotion. We found that sildenafil citrate treatment consistently enhanced 
quiescence at certain concentrations however the result did not reach statistical significance.  
 
 70 
The trend that sildenafil citrate potentially alters satiety quiescence, suggests that it is 
valuable as a tool for studying how enhanced cGMP signaling can affect satiety quiescence in C. 
elegans. Addressing this will help ascertain whether a commercially available drug such as 
sildenafil citrate can be used to treat obesity by suppressing appetite.     
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B. RESULTS 
B.1 Sildenafil Citrate Treated Worms had a Lower Average Speed and Spent more Time at 
Low Speed than Control Worms  
The trend among the increasing concentrations of sildenafil citrate appeared to show 
enhanced quiescence at lower concentrations and then a plateau at concentrations above 20µM 
sildenafil citrate treatment. The amount of time spent at low speed was enhanced for worms 
treated with 10 µM or 20 µM sildenafil citrate in comparison to the DMSO control (Figure 14 
B). However, there appeared to be a plateau in the amount of time spent at low speed for 
concentrations above 20µM sildenafil citrate. Control (water and DMSO) treated worms had a 
higher average speed compared to the 10 µM treated worms, and 20 µM treated worms had a 
lower average speed than 10µM treated worms (Figure 14 A). Treatment with 20µM sildenafil 
citrate showed enhanced quiescence and decreased roaming. Concentrations above 20 µM 
showed an increase in average speed when compared to the 20 µM treated worms. Hidden 
Markov Model analysis permitted the tracking of individual worm satiety state via locomotion 
data (Gallagher 2013). This data shows the total time spent in dwelling (feeding while 
motionless), roaming (actively seeking food), and quiescence states. The results indicate that at 
the 20 µM concentration of sildenafil citrate, quiescence is enhanced compared to both controls 
(Figure 14 C). (Data obtained from experiments with various sildenafil citrate concentrations and 
concurrent DMSO controls demonstrates the same trend described above.) We found that 
enhanced quiescence following sildenafil citrate treatment at certain concentrations was 
enhanced. Statistical significance was observed in only one set of data and not reproduced in 
subsequent experiments. The average of three experiments performed, on the same day showed a 
statistically significant difference between the DMSO control and sildenafil citrate treated worms 
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(20 µM and 30µM). Using the same experimental procedure, we provide three different forms of 
analysis which all indicate the 20µM concentration of sildenafil citrate enhances quiescence. 
These experiments allowed us to determine amount of quiescence at each treatment by several 
parameters.   
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Figure 14A: Representative graph of the average speed of worms treated with water only, DMSO 
only, or various concentrations of sildenafil citrate for 24 hours. (3 worms/ treatment 
concentration; n=3) B: Representative graph of time at low speed of worms treated with water, 
DMSO only, or various concentrations of sildenafil citrate for 24 hours. (3 worms/ treatment 
concentration; n=3) Worm locomotion data for Figure 14A and 14B was monitored via 
YouWorm Tracking system, a custom written program in Matlab, for 1800 frames 
(985ms/1800000ms) and analyzed with a custom written program in Mathematica. C: HMM 
analysis of several worms drug treated with various concentrations of sildenafil citrate. Controls 
were vehicle treated DMSO (1.6%) or non-treated with water (DMSO_C). Red; Roaming; Blue; 
quiescence; Green; dwelling. Numbers listed on the bottom of the Figure 14 C indicate the 
percentage of time spent in each state.  Parenthetical numbers listed to the side indicate the 
number of worms for each treatment.  Worm locomotion data was monitored via YouWorm 
Tracking system for 1800 frames (985ms/1800000ms) and analyzed using a custom written 
program in Matlab.  
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C. DISCUSSION 
C.1 Sildenafil Citrate May Enhance Satiety Quiescence 
The primary aim of this study was to determine whether sildenafil citrate can enhance 
quiescence and address whether the drug is viable for use in determining the mechanism by 
which cGMP enhances quiescence. The PDE inhibitor sildenafil citrate prevents the hydrolysis 
of cGMP, thereby increasing cGMP levels. We hypothesized that an increase in cGMP signal 
duration could mediate downstream effects that result in enhanced quiescence.  Enhanced 
amount of time at low speed and reduced average speed were the parameters used to indicate 
worm quiescence. We observed an enhanced time at low speed and reduced average speed in 
sildenafil citrate treated worms in comparison with the DMSO control. Additionally, HMM 
analysis indicated enhanced quiescence in worms treated with 20 μM sildenafil citrate.  
A statistically significant difference between the DMSO control and sildenafil citrate treated 
worms (20µM and 30 µM) was observed in only one set of data and not reproduced in 
subsequent experiments. Overall, the trend observed was that of enhanced quiescence with 
increasing concentrations of sildenafil citrate until reaching 30µM sildenafil citrate. The 
enhancement of satiety quiescence plateaued at concentrations above 20 µM sildenafil citrate. 
Here, we propose a potential mechanism for the observed trend in satiety quiescence mediated 
by sildenafil citrate. Sildenafil citrate in the C. elegans intestine can act on PDE and multi drug 
resistance (MRP) proteins, which transport molecules through the cell membrane. It has been 
previously determined that satiety quiescence in a C. elegans mrp-6 knockout mutant is reduced 
(Gallagher 2013). Sildenafil citrate acts on PDE in the neuron only and PDE molecules may 
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become saturated in the neuron. At high concentrations MRP may be blocked by sildenafil 
citrate and cGMP cannot leave the gut and there is no more increase in quiescence observed.  
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D. METHODS 
 
D.1 C. elegans Strains and Culture Conditions 
Worms were routinely grown on NGMSR plates(Avery 1993). All worms were maintained at 
20°C on E. coli HB101(Sulston JE 1988). The wild-type strain was C. elegans variant Bristol, 
strain N2. During experimental treatment with sildenafil citrate worms were fed with 
HB101E.coli, cultured overnight and cooled for 24 hours prior to feeding worms.  
D.2 Sildenafil Citrate Treatment Preparation  
Sildenafil citrate was diluted in DMSO to obtain stock solutions of 20 mM and 40 mM. 
Sildenafil citrate diluted with M9 (150 µL of solution) was pipetted onto an NGM plate and 
allowed to dry for one hour. Following the same procedure, a DMSO and M9 solution were 
prepared to use as control treatments. LB (5 ml) was inoculated with E.coli HB101 and allowed 
to incubate on a shaker at 37°C at 250 rpm for 24 hours, then cooled to room temperature for 24 
hours, before centrifugation at 4000 rpm for three minutes and removal of most of the 
supernatant. The E. coli HB101 remaining was pipetted in order to liquefy the bacteria and 
diluted with 2 1:1 serial dilutions in M9 and 10 µL was administered onto each plate and 
permitted to dry for ten minutes.  
D.3 Measuring Locomotive Activity and Analysis  
Approximately 5 L4 wild type worms were moved to the sildenafil citrate containing plates with 
concentrations of 10µM, 20µM, 30µM, or 40µM; 5 L4 worms were placed onto the control 
plates containing 1.6 % DMSO; 5 L4 worms were placed onto the control plates containing 
water; the worms were treated with sildenafil citrate, 1.6% DMSO as a control, or with water as 
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a control, at 20°C for 24 hours. Non-treated (water), vehicle treated (1.6% DMSO), and drug 
treated sildenafil citrate (10µM, 20µM, 30µM, or 40µM) plates were prepared with freshly made 
solutions. The single vehicle treated DMSO control was used in order to control for the potential 
effect of various volumes of DMSO used in concurrent trial controls. The plates were dried for 
one hour, then 4 μL of freshly diluted E. coli HB101 (food for worms) was added to each plate  
After 10 minutes when the plates were dried, a single worm from each treatment plate was 
transferred to an individual treatment plate corresponding to the initial treatment. The worms 
were allowed to habituate for 30 minutes prior to being monitored with cameras for 1800 frames, 
an image was captured every 985ms for 1800000ms. The data was collected with the YouWorm 
Tracking system, a custom written program in Matlab, the locomotion data was analyzed with a 
custom written program in Mathematica as well as HMM analysis to determine quiescence. 
Student t-tests and ANOVA were performed to determine statistical significance.  
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